All Stories

  1. Rapid interrogation of cancer cell of origin through CRISPR editing

    Article • Proceedings of the National Academy of Sciences, August 2021, Proceedings of the National Academy of Sciences

    Dr CHARLES L SAWYERS

  2. The imperative to invest in science has never been greater

    Article • Journal of Clinical Investigation, September 2014, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  3. Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures

    Article • Cell, September 2014, Elsevier

    Dr CHARLES L SAWYERS

  4. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

    Article • Cell, December 2013, Elsevier

    Dr CHARLES L SAWYERS

  5. “N of 1” case reports in the era of whole-genome sequencing

    Article • Journal of Clinical Investigation, October 2013, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  6. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

    Article • Nature Reports Stem Cells, June 2013, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  7. Perspective: Combined forces

    Article • Nature, June 2013, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  8. Overcoming mutation-based resistance to antiandrogens with rational drug design

    Article • eLife, April 2013, eLife

    Yang Shen, Dr CHARLES L SAWYERS, Professor Geoffrey L Greene

  9. β4 Integrin signaling induces expansion of prostate tumor progenitors

    Article • Journal of Clinical Investigation, January 2013, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  10. Annotating MYC status with 89Zr-transferrin imaging

    Article • Nature Reports Stem Cells, September 2012, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  11. Traversing the genomic landscape of prostate cancer from diagnosis to death

    Article • Nature Genetics, May 2012, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  12. Modulators of Prostate Cancer Cell Proliferation and Viability Identified by Short-Hairpin RNA Library Screening

    Article • PLoS ONE, April 2012, PLOS

    Dr CHARLES L SAWYERS

  13. In cancer drug resistance, germline matters too

    Article • Nature Reports Stem Cells, April 2012, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  14. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases

    Article • Cell, March 2012, Elsevier

    Dr CHARLES L SAWYERS

  15. Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia

    Article • PLoS ONE, November 2011, PLOS

    Dr CHARLES L SAWYERS

  16. TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate

    Article • European Urology, November 2011, Elsevier

    Dr CHARLES L SAWYERS

  17. Visualization of the Interstitial Cells of Cajal (ICC) Network in Mice

    Article • Journal of Visualized Experiments, July 2011, MyJove Corporation

    Dr CHARLES L SAWYERS

  18. THE ANDROGEN RECEPTOR

    Article • July 2011, World Scientific Pub Co Pte Lt

    Dr CHARLES L SAWYERS

  19. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors

    Article • Cancer Genetics, July 2011, Elsevier

    Dr CHARLES L SAWYERS

  20. Profile of Charles L. Sawyers

    Article • Proceedings of the National Academy of Sciences, May 2011, Proceedings of the National Academy of Sciences

    Dr CHARLES L SAWYERS

  21. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

    Article • Cancer Cell, May 2011, Elsevier

    Dr CHARLES L SAWYERS

  22. Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award

    Article • Journal of Clinical Investigation, April 2011, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  23. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors

    Article • PLoS ONE, March 2011, PLOS

    Dr CHARLES L SAWYERS

  24. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

    Article • Nature, March 2011, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  25. How melanomas bypass new therapy

    Article • Nature, December 2010, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  26. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours

    Article • Nature, October 2010, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  27. Even Better Kinase Inhibitors for Chronic Myeloid Leukemia

    Article • New England Journal of Medicine, June 2010, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  28. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib

    Article • Leukemia Research, June 2010, Elsevier

    Dr CHARLES L SAWYERS

  29. Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion-Positive Prostate Cancers

    Article • Cancer Cell, May 2010, Elsevier

    Dr CHARLES L SAWYERS

  30. Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)

    Article • Journal of Medicinal Chemistry, April 2010, American Chemical Society (ACS)

    Dr CHARLES L SAWYERS

  31. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model

    Article • The Prostate, November 2009, Wiley

    Dr CHARLES L SAWYERS

  32. Shifting paradigms: the seeds of oncogene addiction

    Article • Nature Reports Stem Cells, October 2009, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  33. Brian Druker, Charles Sawyers win Lasker award

    Article • Cancer Biology & Therapy, September 2009, Taylor & Francis

    Dr CHARLES L SAWYERS

  34. Finding and Drugging the Vulnerabilities of RAS-Dependent Cancers

    Article • Cell, May 2009, Elsevier

    Dr CHARLES L SAWYERS

  35. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

    Article • Nature Genetics, April 2009, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  36. CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

    Article • The Journal of Urology, April 2009, Wolters Kluwer Health

    Dr CHARLES L SAWYERS

  37. Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells

    Article • The Prostate, January 2009, Wiley

    Dr CHARLES L SAWYERS

  38. Molecular Biology of Novel Targets Identified Through Study of Castration-Recurrent Prostate Cancer

    Article • January 2009, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  39. Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis

    Article • Cancer Cell, December 2008, Elsevier

    Dr CHARLES L SAWYERS

  40. Translational research: are we on the right track?

    Article • Journal of Clinical Investigation, November 2008, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  41. Targeting the androgen receptor pathway in prostate cancer

    Article • Current Opinion in Pharmacology, August 2008, Elsevier

    Dr CHARLES L SAWYERS

  42. The cancer biomarker problem

    Article • Nature, April 2008, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  43. Something lost — something gained: the ASCI begins its second century

    Article • Journal of Clinical Investigation, April 2008, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  44. Mixing cocktails

    Article • Nature, October 2007, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  45. Where lies the blame for resistance—tumor or host?

    Article • Nature Reports Stem Cells, October 2007, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  46. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

    Article • Journal of Clinical Investigation, September 2007, American Society for Clinical Investigation

    Dr CHARLES L SAWYERS

  47. Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN

    Article • Cancer Cell, June 2007, Elsevier

    Dr CHARLES L SAWYERS

  48. Will Kinase Inhibitors Have a Dark Side?

    Article • New England Journal of Medicine, July 2006, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  49. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Article • New England Journal of Medicine, June 2006, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  50. Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies

    Article • The Scientific World JOURNAL, January 2006, Hindawi Publishing Corporation

    Dr CHARLES L SAWYERS

  51. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

    Article • Nature Reports Stem Cells, December 2005, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  52. Myc-driven murine prostate cancer shares molecular features with human prostate tumors

    Article • Cancer Cell, December 2005, Elsevier

    Dr CHARLES L SAWYERS

  53. Calculated resistance in cancer

    Article • Nature Reports Stem Cells, August 2005, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  54. Dynamics of chronic myeloid leukaemia

    Article • June 2005

    Dr CHARLES L SAWYERS

  55. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes

    Article • April 2005

    Dr CHARLES L SAWYERS

  56. Cross-species comparisons of cancer signaling

    Article • Nature Genetics, January 2005, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  57. Targeted cancer therapy

    Article • November 2004

    Dr CHARLES L SAWYERS

  58. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

    Article • Cancer Cell, November 2004, Elsevier

    Dr CHARLES L SAWYERS

  59. Prostate Cancer

    Article • October 2004, Wiley

    Dr CHARLES L SAWYERS

  60. Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

    Article • New England Journal of Medicine, August 2004, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  61. TORward AKTually useful mouse models

    Article • Nature Reports Stem Cells, June 2004, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  62. Molecular determinants of resistance to antiandrogen therapy

    Article • Nature Reports Stem Cells, December 2003, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  63. Will mTOR inhibitors make it as cancer drugs?

    Article • Cancer Cell, November 2003, Elsevier

    Dr CHARLES L SAWYERS

  64. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

    Article • Oncogene, October 2003, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  65. Myc-driven murine prostate cancer shares molecular features with human prostate tumors

    Article • Cancer Cell, September 2003, Elsevier

    Dr CHARLES L SAWYERS

  66. MicroPET imaging of prostate cancer in LNCAP‐SR39TK‐GFP mouse xenografts

    Article • The Prostate, March 2003, Wiley

    Dr CHARLES L SAWYERS

  67. The emergence of resistance to targeted cancer therapeutics

    Article • Pharmacogenomics, September 2002, Future Medicine

    Dr CHARLES L SAWYERS

  68. Survival signaling mediated by c-Jun NH2-terminal kinase in transformed B lymphoblasts

    Article • Nature Genetics, August 2002, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  69. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

    Article • Cancer Cell, August 2002, Elsevier

    Dr CHARLES L SAWYERS

  70. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation

    Article • Oncogene, July 2002, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  71. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization

    Article • Genes Chromosomes and Cancer, July 2002, Wiley

    Dr CHARLES L SAWYERS

  72. Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease

    Article • European Journal of Nuclear Medicine and Molecular Imaging, July 2002, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  73. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells

    Article • Oncogene, July 2002, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  74. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

    Article • Nature Reviews Cancer, July 2002, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  75. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

    Article • Current Opinion in Hematology, July 2002, Wolters Kluwer Health

    Dr CHARLES L SAWYERS

  76. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

    Article • Cancer Cell, June 2002, Elsevier

    Dr CHARLES L SAWYERS

  77. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

    Article • New England Journal of Medicine, February 2002, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  78. Disabling Abl—Perspectives on Abl kinase regulation and cancer therapeutics

    Article • Cancer Cell, February 2002, Elsevier

    Dr CHARLES L SAWYERS

  79. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia

    Article • Seminars in Hematology, July 2001, Elsevier

    Dr CHARLES L SAWYERS

  80. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

    Article • Seminars in Hematology, July 2001, Elsevier

    Dr CHARLES L SAWYERS

  81. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

    Article • Seminars in Hematology, July 2001, Elsevier

    Dr CHARLES L SAWYERS

  82. Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia

    Article • Seminars in Hematology, July 2001, Elsevier

    Dr CHARLES L SAWYERS

  83. Mutations in the mitotic check point gene, MAD1L1, in human cancers

    Article • Oncogene, May 2001, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  84. Defining a common region of deletion at 13q21 in human cancers

    Article • Genes Chromosomes and Cancer, May 2001, Wiley

    Dr CHARLES L SAWYERS

  85. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

    Article • New England Journal of Medicine, April 2001, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  86. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

    Article • New England Journal of Medicine, April 2001, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  87. Bcr-abl kinase inhibition as the basis of therapy for cml

    Article • Experimental Hematology, July 2000, Elsevier

    Dr CHARLES L SAWYERS

  88. Chronic Myeloid Leukemia

    Article • New England Journal of Medicine, April 1999, New England Journal of Medicine (NEJM/MMS)

    Dr CHARLES L SAWYERS

  89. A TYPE II TRANSMEMBRANE GLYCOPROTEIN ASSOCIATED WITH OSTEOGENESIS CAN ACCELERATE ANDROGEN-INDEPENDENT PROSTATE CANCER PROGRESSION IN VIVO

    Article • The Journal of Urology, April 1999, Wolters Kluwer Health

    Dr CHARLES L SAWYERS

  90. SYNERGISM OF IONIZING RADIATION AND GENE THERAPY WITH THE REPLICATION COMPETENT CN706 ADENOVIRUS IN THE LAPC-4 PROSTATE CANCER CELL LINE

    Article • The Journal of Urology, April 1999, Wolters Kluwer Health

    Dr CHARLES L SAWYERS

  91. Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes

    Article • Leukemia Research, December 1998, Elsevier

    Dr CHARLES L SAWYERS

  92. Functional role for the c-Abl tyrosine kinase in meiosis I

    Article • Oncogene, April 1998, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  93. Signal transduction by wild-type and leukemogenic Abl proteins

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, December 1997, Elsevier

    Dr CHARLES L SAWYERS

  94. 3 Signal transduction pathways involved in BCR-ABL transformation

    Article • Baillière s Clinical Haematology, June 1997, Elsevier

    Dr CHARLES L SAWYERS

  95. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

    Article • Nature Reports Stem Cells, April 1997, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  96. Molecular genetics of acute leukaemia

    Article • The Lancet, January 1997, Elsevier

    Dr CHARLES L SAWYERS

  97. Signal transduction-based strategies for the treatment of chronic myelogenous leukemia

    Article • Molecular Medicine Today, December 1996, Elsevier

    Dr CHARLES L SAWYERS

  98. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage

    Article • Nature, July 1996, Springer Science + Business Media

    Dr CHARLES L SAWYERS

  99. Genetic Approaches to Defining Signaling by the CML-Associated Tyrosine kinase BCR-ABL1

    Article • January 1996, Springer Science + Business Media

    Dr CHARLES L SAWYERS, Professor Andrei Goga

  100. Abl

    Article • January 1995, Elsevier

    Dr CHARLES L SAWYERS

  101. Positive and Negative Growth Effects of Abl Genes

    Article • January 1995, Springer Science + Business Media

    Dr CHARLES L SAWYERS, Professor Andrei Goga

  102. In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer

    Article • Cancer, October 1994, Wiley

    Dr CHARLES L SAWYERS

  103. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about

    Article • Cell, April 1994, Elsevier

    Dr CHARLES L SAWYERS

  104. The nuclear tyrosine kinase c-abl negatively regulates cell growth

    Article • Cell, April 1994, Elsevier

    Dr CHARLES L SAWYERS

  105. The Role of MYC in Transformation by BCR-ABL

    Article • Leukemia & Lymphoma, January 1993, Taylor & Francis

    Dr CHARLES L SAWYERS

  106. Dominant negative MYC blocks transformation by ABL oncogenes

    Article • Cell, September 1992, Elsevier

    Dr CHARLES L SAWYERS

  107. Production of granulocyte-macrophage colony-stimulating factor in two patients with lung cancer, leukocytosis, and eosinophilia

    Article • Cancer, March 1992, Wiley

    Dr CHARLES L SAWYERS

  108. Chronic Myeloid Leukemia

    Article • Springer Science + Business Media

    Dr CHARLES L SAWYERS

  109. Xenograft Models and the Molecular Biology of Human Prostate Cancer

    Article • Springer Science + Business Media

    Dr CHARLES L SAWYERS